tbuckley/cabot-search huggingface dataset:
A rare case of peripancreatic Castleman’s disease diagnosed preoperatively by endoscopic ultrasound-guided fine needle aspiration
Authors: M. Khashab, M. Canto, V. Singh, S. Ali, E. Fishman, B. Edil, S. Giday
Journal: Endoscopy (2011)

Castleman's disease is a rare lymphoproliferative disorder of unknown etiology and has three pathologic variants: hyaline-vascular (HV), plasma cell (PC), and mixed type [1]. Two clinically relevant subtypes exist, the unicentric and multicentric variants. Unicentric pancreatic Castleman's disease is very rare with only 13 reported cases [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14]. We report on the endosonographic features of pancreatic Castleman's disease and its preoperative diagnosis by endoscopic ultrasound-guided fine needle aspiration (EUS-FNA).
OC-050 Inpatient paediatric UC care in the UK in 2011 is characterised by increasing rates of rescue therapy and stool cultures but low use of pucai scores
Authors: R K Russell, A Protheroe, M Roughton, N Croft, M S Murphy, C Spray, A Rodrigues, D C Wilson, J Puntis, M Cosgrove, A Tarnock, P Rao, C Down, I Arnott, S Mitton
Journal: Gut (2012)

<h3>Introduction</h3> Paediatric UC care is variable in the UK and appropriate clinical guidelines are very recent. Acute severe UC is rare with only a few cases presenting annually to each tertiary hospital. <h3>Methods</h3> UC patients aged &lt;17 years admitted to 23 UK paediatric hospitals had clinical details collected as part of the UK paediatric IBD audit (September 2010–2011). Each site was asked to enter up to 20 cases admitted electively or as an emergency, including patients who were having surgery. Day cases and patients who were admitted solely for diagnostic endoscopy were excluded. Comparative data for some items was available from the previous UK audit conducted in 2008. <h3>Results</h3> 176 patients (98 males) of median age 13 years (IQR 10–13) were included in the audit; 22 were elective surgical admissions, 47 new diagnoses and 107 needed acute medical care for known UC. Median length of stay was 6 days (IQR 3–10); there were no deaths. 73% of patients with established disease had a pancolitis and 10% had co-existent liver disease. 88 (70%) of 126 patients with active disease had standard stool cultures performed (2% were positive) and 57 (45%) had <i>C difficile</i> toxin tested (none positive). Stool sample collection rates had improved significantly compared to the 2008 audit (70% vs 52%, p=0.001). 38% of emergency admissions had a plain abdominal XR taken on admission, but only 19% had a specific disease activity index (PUCAI score) recorded. There were three cases of toxic megacolon and 3 of thromboses. Rates of heparinisation were low but higher than in the 2008 audit (11% vs 2%, p=0.002). 71% of patients treated with steroids responded to treatment. 20 patients received 2nd line (rescue) therapy, of whom eight received infliximab, 11 Cyclosporin and one both, with an overall response rate of 90%; nine went to surgery without 2nd line medical therapy. Rescue therapy usage was significantly higher than in the 2008 audit (52% vs 26%, p=0.03). Overall, 71% of non-elective UC admissions were seen by an IBD nurse. <h3>Conclusion</h3> There were signs of improving UC care from 2008 to 2011 with significantly increased rates of stool culture sampling and use of rescue therapy, but the majority of sites did not use PUCAI scores to assess patients on emergency admission. <h3>Competing interests</h3> None declared.
THU0045 Score and framingham predict cv disease incidence in RA patients better than intima-media thickness:
Authors: A.M. van Sijl, I.A. van den Oever, H.G. Raterman, M.J. Peters, V.P. van Halm, M. Boers, Y.M. Smulders, A.E. Voskuyl, M.T. Nurmohamed
Journal: Annals of the Rheumatic Diseases (2012)

<h3>Background</h3> Rheumatoid arthritis (RA) is a chronic inflammatory disease with an increased cardiovascular (CV) risk. Carotid intima-media thickness (cIMT) predicts CV events in the general population, and hence, is used as a non-invasive screening tool to identify patients at high CV risk. In RA, it is still unclear whether estimated 10-year CV risk models, such as the Systematic Coronary Risk Evaluation (SCORE) and Framingham accurately predict CV disease incidence or whether cIMT measurement can equally predict CV disease incidence. <h3>Objectives</h3> To investigate the predictive value of SCORE- and Framingham risk models and cIMT for future CV events in RA. <h3>Methods</h3> CARRΈ is an ongoing cohort study of CV disease in RA. In a subpopulation (n=141) we measured cIMT at baseline; Of those, 120 had no prior CV disease and 10-year risk of fatal and nonfatal CV disease was calculated. We compared these calculations with actual CV events recorded in a mean follow-up of 9 years. During this time, IMT was measured three times. Univariate logistic regression analyses (with standardized odds ratios) investigated the extent to which individual CV risk factors, SCORE, Framingham and cIMT predicted CV disease incidence. <h3>Results</h3> Thirteen RA patients (incidence rate: 13.5%, 95% confidence interval (CI): 7.8-23.2) developed a CV event, of which four of these events were fatal (incidence rate: 4.2%, 95%&gt;CI: 1.6-11.1). SCORE- and Framingham predictions were very close to actual CV mortality and morbidity and significantly predicted (fatal) CV events. cIMT also showed a trend in prediction of CV disease. cIMT progressed with an annual rate of 0.005mm. <h3>Conclusions</h3> This long term follow up study underscores the value of SCORE and Framingham in prediction of CV disease incidence, also in RA. In this study of RA patients the evidence for cIMT, a surrogate marker of CV disease in the general population, had no predictive value. <h3>Disclosure of Interest</h3> None Declared
PSYCHOLOGICAL STRESS AND MATERNAL CORTISOL WHEN CARRYING A FETUS WITH CONGENITAL HEART DISEASE
Authors: Brooke Davey, Zhi-Yun Tian, Agbenu Ejembi, Denise Donaghue, Jill Combs, Okan Elci, Suzanne Levy, Jack Rychik, Guy Diamond
Journal: Journal of the American College of Cardiology (2016)
Fully covered metallic stents in biliary stenosis after orthotopic liver transplantation
Authors: I. Tarantino, M. Traina, F. Mocciaro, L. Barresi, G. Curcio, M. Di Pisa, A. Granata, R. Volpes, B. Gridelli
Journal: Endoscopy (2012)

Data from a preliminary study suggested that the placement of a fully covered metal stent may be a valid alternative to surgery in patients who do not respond to standard endoscopic treatment. The aims of the current study were to evaluate the clinical success of self-expandable metallic stents (SEMS) in a large cohort of patients and with a long followup,and the effectiveness of SEMS placement as a first-line procedure.Between January 2008 and August 2010, 54 consecutive patients with biliary complications following orthotopic liver transplantation were treated with SEMS placement:39 after failure of conventional endoscopic therapy (Group I), and 15 with no previous endoscopic treatment who were undergoing SEMS placement as first-line treatment for complications(Group II).In Group I, resolution after SEMS removal was observed in 71.8% of patients. Mean followup after resolution was 22.1 ±10 months. Recurrence of the complication was observed in 14.3%of patients after a mean of 8.5 months and SEMS migration was observed in 33.3% of patients. In Group II, resolution was observed in 53.3% of patients.Mean follow-up after resolution was 14.4±2.2 months. Recurrence was observed in 25% of patients and SEMS migration was observed in 46.7 %.For endotherapy of biliary complications after orthotopic liver transplantation, metallic stents should not be used as the primary modality. In patients in whom the standard approach fails, treatment with temporary SEMS placement can solve biliary complications in almost three-quarters of cases; however stent migration(33 %) remains a problem.
P881 COGNITIVE IMPAIRMENT AND ELECTROENCEPHALOGRAPHIC ALTERATIONS BEFORE AND AFTER LIVER TRANSPLANTATION: WHAT IS REVERSIBLE?
Authors: F. Campagna, S. Montagnese, S. Schiff, A. Biancardi, D. Mapelli, P. Angeli, C. Poci, U. Cillo, C. Merkel, A. Gatta, P. Amodio
Journal: Journal of Hepatology (2014)
P116 Testing antioxidant and anti-inflammatory therapies in a complex lung tissue model
Authors: T. S. Singh, F. R. Razali, M. N. North, T. W. Wilkinson, B. L. N. Nicholas
Journal: Thorax (2011)

<h3></h3> COPD is a disease of global importance and its primary cause airway inflammation as a consequence of cigarette smoking is well described. However, there remains a lack ofeffective therapies for this important condition. Animal models of disease are limited in their predictive utility and therefore creation of a complex, human disease modelis an important step for testing new therapeutic interventions. We therefore established a tissue model of oxidative and inflammatory responses to relevant triggers—cigarette smoke and LPS and determined the impact of interventions in the optimised system. <h3>Methods</h3> Human lung tissueexplants from the resected lobes of six consented patients undergoing lobectomy were used. Uniform tissue explants were established on a novel culture system and then treated with CSE and LPS before the supernatants were collected optimal dosing was determined. Treatments and control experiments were performed with the anti-oxidant Vitamin C and fluticasone. Inflammatory readouts were measured by ELISA; TNFa, IL-8 and MMP-9. <h3>Results</h3> Lung tissue treated with CSE showed a dose-dependent increase in IL-8 and MMP-9 secretion across a range 0.6250%–20% CSE. IL-8 response to 20% CSE was 71592.21 pg/mg/ml ±4680.7 SE compared to non-stimulated tissue 14 177 pg/mg/ml ±1088 SE (n=6, p&lt;0.001), MMP-9 response to 20% CSE 206 pg/mg/ml ±30.55SE vs control 104 pg/mg/ml ±4.49 SE (n=6, p&lt;0.001).However no demonstrable rise in TNF-α secretion from tissue treatedwith CSE was detectable. With LPS stimulation both TNF-α and IL-8 responses demonstrated adose-dependent increase within the range 0.01–100 ng/ml (n=5, p=0.0003). <h3>Treatment effects</h3> Stimulated IL-8 and MMP-9 secretion was significantly reduced in tissue treated with 0.1% vitamin C. 25% reduction in IL8 (n=3, p=0.065) and 32% reduction in MMP9 (n=3, p=0.0133). Fluticasone treatment reduced LPS induced TNF-α and IL-8 in a dose dependent manner (n=4, p=0.03). <h3>Conclusions</h3> A human lung tissue model of smoke and LPS induced inflammation demonstrates the importance of selecting appropriate readouts for a given stimulus or treatment and hence a potential utility in selecting trial endpoints. Furthermore it demonstrates that vitamin C and corticosteroids can reduce oxidative stress and inflammation in a complex tissue system- their combined effects warrant investigation in COPD.
Abstract LB-235: SUMO-1 modification represses CPAP transcriptional co-activator activity in TNFα-induced NF-κB signaling pathway
Authors: Shu-Ting Yang, Liang-Yi Hung
Journal: Cancer Research (2010)

Abstract The transcription factor nuclear factor-κB (NF-κB) is an important regulator in inflammation, immune responses, apoptosis, cell proliferation and differentiation. CPAP (Centrosomal protein P4.1-associated protein), which plays important roles on centrosomal functions, is previously identified as the transcriptional coactivator for NF-κB. Here, we have demonstrated that decreased expression of CPAP by siRNA can attenuate NF-κB-mediated genes expression under TNFα stimulus. On the contrary, overexpressed CPAP contributes to the NF-κB-driven transcriptional activation. Immunoflourescence data showed that the nuclear localization of CPAP is induced by TNFα stimulus. Chromatin immunoprecipitation assay further indicated that CPAP was recruited to COX-2 promoter region under TNF treatment. We found that the NF-κB signaling pathway is activated by CPAP through recruiting more IKKß to the inactivated NF-κB complex to enhance the degradation of IκB and the phosphorylation of p65. Importantly, CPAP was covalently modified by small ubiquitin-related modifier-1 (SUMO-1) protein under TNFα stimulus, and the specific acceptor sites were located in the C-terminal of CPAP. Interestingly, when overexpressing SUMO-deficient CPAP in A549 cells, the TNFα-induced NF-κB-mediated genes expression was up-regulated. Co-immunoprecipitation assay showed that the association of IKKß to NF-κB complex was augmented by SUMO-deficient CPAP than wild type CPAP. Taken together, these results suggest that there might be a mechanism for the SUMOylation of CPAP in modulating the activity of NF-κB. The detailed machinery for SUMOylated CPAP in the TNFα-induced NF-κB activation is currently under investigation. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr LB-235.
P59 The Characterisation of Cough in Lung Cancer
Authors: O Buffin, J Burnham, J Smith, F Blackhall, A Harle
Journal: Thorax (2013)

<h3>Introduction</h3> Cough in lung cancer (LC) is a distressing symptom with a significant impact on quality of life (QoL), and no effective therapies. Little data is available defining the proportion of LC patients affected by cough or its impact. This study determines the prevalence and characteristics of cough in LC using validated assessment tools, including the new LC-specific impact scale: Manchester Cough in Lung Cancer Scale (MCLCS). <h3>Patients and methods</h3> Consecutive patients attending a single-centre LC outpatient oncology clinic were enrolled over a 5-week period. Every patient was asked “do you have a cough?” Patients who answered yes had their cough assessed using a cough severity Visual Analogue Scale (VAS) and the MCLCS. Clinical and demographic data were collected. <h3>Result</h3> A total of 224 patients were enrolled; 55% male; 10% never smoked; 31% small cell lung cancer (SCLC) and 52% had a performance status (PS) of 2 3. The cough prevalence was 58%; 53% felt their cough warranted treatment and 23% reported painful cough. Mean MCLCS 22.7 (8.1 ± SD, range 0 50: 50 = worst cough QoL) and VAS scores were 36mm (21.3 ± SD). Painful coughs scored higher on the VAS and MCLCS (mean VAS 45.7mm vs.33.3, p = 0.034, mean MCLCS 28.0 vs. 19.6 p&gt;0.005). Coughs warranting treatment also scored higher on the VAS and MCLCS (mean VAS 47.2 vs. 23.8 p&gt;0.005, mean MCLCS 25.4 vs. 17.1, p&gt;0.005 respectively). Cough prevalence was higher in patients off anti-cancer therapy (63% vs. 50%, p = 0.048). Cough had a greater impact on mean MCLCS scores in poor PS patients (p &gt;0.0005). <h3>Conclusion</h3> This is the first study to assess the prevalence of cough in a large clinical cohort of outpatients with LC and to characterise cough using validated assessment tools. Cough was most severe coughs and had greatest impact on quality of life in patients who described their cough as painful or warranting treatment. The MCLCS and VAS are simple cough assessment tools that can be readily used in research and clinical practice to better evaluate cough and facilitate the development of effective cough therapies.
AB1336 Clinical characteristics of anti-TNF agents-related tuberculosis in ankylosing spondylitis compared with rheumatoid arthritis:
Authors: H.W. Kim, Y.I. Yun, J.A. Yang, Y.W. Song, E.B. Lee
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Ankylosing spondylitis (AS) is a rheumatologic disease for which anti-TNF agents are effective. Tuberculosis (TBc) is one of the serious infectious complications of anti-TNF agents. However, clinical characteristics of anti-TNF agents-related TBc in AS are not well described. <h3>Objectives</h3> To investigate the clinical characteristics of active TBc which develops in AS patients after taking anti-TNF agents. <h3>Methods</h3> We enrolled all the patients with AS or rheumatoid arthritis (RA) who took anti-TNF agents at Seoul National University Hospital between Jan 2001 and Aug 2011. Medical records were reviewed for all the patients. TBc was defined as presence of <i>M. tuberculosis</i> in culture or typical radiographic findings and clinical response to anti-TBc medication. Clinical characteristics of AS patients who developed TBc were compared with those of RA. <h3>Results</h3> Median follow-up duration (range) were 30.7 (1.9∼48.9) months for AS and 19.6 (8.6∼47.2) months for RA. <h3>Conclusions</h3> When anti-TNF agents are prescribed in AS, TBc can develop as frequently as in RA. TBc developed later in AS than in RA after initiation of anti-TNF agents. Extrapulmonary tuberculosis was prevalent as in RA. Current prophylaxis method does not seem to adequately prevent tuberculosis in AS. <h3>Disclosure of Interest</h3> None Declared
Effect of Dietary Stearic Acid on Plasma Cholesterol and Lipoprotein Levels
Authors: Andrea Bonanome, Scott M. Grundy
Journal: New England Journal of Medicine (1988)

We studied the metabolic effects of stearic acid (18:0) on plasma lipoprotein levels in 11 subjects during three dietary periods of three weeks each. The three liquid-formula diets, which were used in random order, were high in palmitic acid (16:0), stearic acid, and oleic acid (18:1), respectively. Caloric intakes were the same during the three periods. As compared with the values observed when the subjects were on the high-palmitic-acid diet, plasma total cholesterol decreased by an average of 14 percent during consumption of the high-stearic-acid diet (P less than 0.005) and by 10 percent during consumption of the high-oleic-acid diet (P less than 0.02). Low-density lipoprotein cholesterol levels fell by 21 percent in subjects on the high-stearic-acid diet (P less than 0.005) and by 15 percent in subjects on the high-oleic-acid diet (P less than 0.005). No significant differences were observed in the plasma levels of triglycerides or high-density lipoprotein cholesterol among the three diets. Measurements of the intestinal absorption of palmitic, stearic, and oleic acids revealed essentially complete absorption of each during the three dietary periods. The oleic acid content of plasma triglycerides and cholesteryl esters increased significantly during the high-stearic-acid period, suggesting that stearic acid is rapidly converted to oleic acid. We conclude that stearic acid appears to be as effective as oleic acid in lowering plasma cholesterol levels when either replaces palmitic acid in the diet.
Abstract 2253: Proteases and cytokines in the transition from preinvasive DCIS to invasive breast carcinoma
Authors: Mansoureh Sameni, Arulselvi Anbalagan, Bonnie F. Sloane
Journal: Cancer Research (2010)

Abstract The transition from preinvasive ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC) involves alterations in proteolytic pathways of both epithelial and stromal cells. Infiltration of macrophages, angiogenesis and secretion of chemotactic molecules by DCIS and surrounding stromal cells also facilitate this transition. We have developed a 3D coculture model, MAME (mammary architecture and microenvironment engineering), to study the role of proteases and cytokines in the progression from pre-invasive DCIS to IDC. MAME-A recapitulates the architecture of normal human breast tissue with the epithelial and stromal components growing in overlays of basement membrane and stromal collagen, respectively. In MAME-B, the stromal collagen is eliminated. The cells used in our studies were human MCF10.DCIS cells, WS-12Ti human breast tumor-associated fibroblasts, U937 human monocytes and human umbilical vein endothelial cells (HUVEC). We analyzed proteolysis through live cell imaging of the degradation of quenched fluorescent matrix proteins [DQ-collagen I™ mixed with collagen I and DQ-collagen IV™ mixed with reconstituted basement membrane (rBM)]. DCIS cells in MAME-A cocultures with fibroblasts exhibited invasiveness at 24 days, yet at only 16 days in MAME-B cocultures. Expression and secretion of cytokines, especially IL-6, were elevated in these cocultures. The invasiveness of the DCIS cells in the cocultures with fibroblasts could be reduced by addition of neutralizing antibody to IL-6. Addition of either monocytes or endothelial cells reduced the time at which invasiveness occurred to as early as 4 days in MAME-B cocultures. Addition of monocytes increased secretion of monocyte chemoattractant protein-1 (MCP-1), IL-8 and GRO. The combination of a neutralizing antibody to hMCP-1 and a receptor-blocking antibody to hCXCR2 (a receptor for IL-8 and GRO) reduced invasiveness more effectively than did either of the antibodies used alone. When HUVEC were grown in MAME-B cocultures with DCIS or DCIS and fibroblasts, the HUVEC grew into a network of tubules with distinct lumens over a period of 4 days. In 3D and 4D reconstructions of these same cocultures, DCIS cells could be seen to migrate toward the HUVEC tubules and invade into their lumens. These phenomena occurred in parallel with increases in proteolysis and in expression and secretion of the cytokines MCP-1, IL-8, RANTES and GRO. The MAME models provide a system for the study of proteolytic and cytokine pathways and the interactions between these pathways that are associated with the transition from DCIS to invasive ductal carcinoma. This model could be used as an in vitro tool for screening drugs that target these pathways. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 2253.
AB0853 Uveitis as First Manifestation of Syphilis. Report of 11 Cases from A Single Center
Authors: M. Santos-Gόmez, V. Calvo-Río, J. Cañal-Villanueva, R. Blanco-Alonso, J.A. Ventosa-Ayarza, D. Hera-Vegas, F. Ortiz-Sanjuán, J. Loricera, C. Martínez-Dubois, F.J. Rueda-Gotor, M.Ά. González Gay
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Objectives</h3> Syphilitic Uveitis (SU) may be the first manifestation of syphilis. SU may be indistinguishable morphologically from other etiologies causing uveitis. Our aim was to study and describe the SU as first manifestation of syphilis. <h3>Methods</h3> We describe 11 patients with SU diagnosed at our Hospital from 2006 to 2013. Diagnosis was based on active uveitis and specific microbiological test. To evaluate neurological involvement, a lumbar puncture was performed in 9 patients. <h3>Results</h3> Eleven patients (3 women/8 men) with a mean age of 45.8±13.8 years (range 26 -70) were diagnosed as having SU. First syphilitic manifestation was uveitis (n=9) and mucocutaneous lesions (n=2). The pattern of uveitis were: posterior (n=6), panuveitis (n=3), and anterior (n=2). Ocular involvement was unilateral (n=8) and bilateral (n=3). The median diagnostic delay was 0,75 months (IQR 0-2) (range 0-12). Positive serology of HIV (n=3) and neurosyphilis (n=2) were observed. Treatment was based on penicillin G (4 million-units/4h/i.v.) for 14 days (n=8) and for 21 days (n=2), and doxicillin 100 mg/12h for 28 days, because of allergic condition (n=1). We had a relapse in one case treated initially with benzathine penicillin/1.2 MU/i.m x 3 day, and then with penicillin G 4MU/4h ev x 21 days. The median of visual acuity improved from 0,1 (IQR 0,05-0,3; range 0-0.8) to 0.6 (IQR 0,05-0,9; range 0,05-1) after treatment. The main ocular complications of SU were complete unilateral ocular blindness (n=3), retina detachment (n=2), cataract (n=1), and increased ocular tension (n=1). <h3>Conclusions</h3> It is recommended to include SU in the differential diagnosis of uveitis. <h3>Acknowledgements</h3> This study was supported by a grant from "Fondo de Investigaciones Sanitarias"PI12/00193 (Spain). This work was also partially supported by RETICS Programs, RD08/0075 (RIER) and RD12/0009/0013 from "Instituto de Salud Carlos III" (ISCIII) (Spain). <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.3879